子公司管理制度 第一章 总则 第一条 南京海辰药业股份有限公司(以下简称"公司")为加强对子公司的 管理控制，规范子公司行为，保证子公司规范运作和依法经营，根据《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》《深 圳证券交易所创业板股票上市规则》（以下简称"《创业板上市规则》"）、《南 京海辰药业股份有限公司章程》（以下简称"《公司章程》"）及公司实际情况， 特制定本制度。 第二条 本制度所称"子公司"是指公司依法设立的，具有独立法人资格主 体的公司。按其设立形式不同，分别包括： （一）独资设立的全资子公司； （二）与其他单位或自然人共同出资设立的，公司持有其 50%以上的股权， 或者持股 50%以下但能够决定其董事会半数以上成员的组成，或者通过协议或其 他安排能够实际控制的公司。 第三条 本制度适用于公司及公司子公司。公司推荐或委派至各子公司的董 事、监事、高级管理人员应该严格执行本制度，并应依照本制度及时、有效地做 好管理、指导、监督等工作。 第四条 子公司在公司总体战略目标框架下，独立经营和自主管理，合法有 效的运作企业法人财产，同时，应当执行公司对子公司的各项制度规定。 ...

南京海辰药业股份有限公司 董事和高级管理人员持有和买卖本公司股票管理制度 第一章 总则 第一条 为了便于南京海辰药业股份有限公司（以下简称"本公司"）对董事 和高级管理人员持有及买卖本公司股票的管理，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》、《上市公司 股东减持股份管理暂行办法》、《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》、《深圳证券交易所上市公司自律监管指引第 18 号— —股东及董事、高级管理人员减持股份》、《深圳证券交易所上市公司自律监管指 引第 10 号——股份变动管理》等法律法规及《公司章程》的规定，结合公司实际情 况，制定本制度。 第二条 本制度适用于公司董事、高级管理人员持有及买卖公司股票及其衍生 品种的管理。 公司董事、高级管理人员存在更严于本制度的规定、与持有和买卖本公司股票 相关的承诺且不违反法律、法规和规范性文件规定的，按相关规定或承诺内容执行。 公司董事、高级管理人员委托他人代行买卖股票及其衍生品种的，视作本人所 为，也应 ...

第三条 公司董事、高级管理人员以及与年报信息披露相关的其他人员在年 报信息披露工作中违反国家有关法律、法规、规范性文件以及公司规章制度，未 勤勉尽责或者不履行职责，导致年报信息披露发生重大差错，应当按照本制度的 规定追究其责任。 南京海辰药业股份有限公司 年报信息披露重大差错责任追究制度 第一章 总 则 第一条 为了进一步提高南京海辰药业股份有限公司（以下简称"公司"）规 范运作水平，加大对年报信息披露责任人的问责力度，提高年报信息披露的质量 和透明度，增强年报信息披露的真实性、准确性、完整性和及时性，根据《中华 人民共和国证券法》（以下简称"《证券法》"）《中华人民共和国会计法》《上市公 司信息披露管理办法》《上市公司治理准则》《深圳证券交易所创业板股票上市规 则》（以下简称"《创业板上市规则》"）等法律、法规、规范性文件及《南京海辰 药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结合公司的实 际情况，特制定本制度。 第二条 公司有关人员应当严格执行《企业会计准则》及相关规定，严格遵 守公司与财务报告相关的内部控制制度，确保财务报告真实、公允地反映公司的 财务状况、经营成果和现金流量。公司有 ...

1.本年度生产经营情况，特别是经营状况或环境发生的变化； 2.公司财务状况； 3.募集资金的使用； 4.重大投资情况； 南京海辰药业股份有限公司 独立董事年报工作制度 第一条 为进一步完善南京海辰药业股份有限公司（以下简称"本公司"）的 治理机制，健全公司内部控制制度，明确独立董事在年报信息披露中的责任，根 据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《上市公司独立董事履职指引》等相关法律法规以及《独立董事工作制度》《公 司章程》等有关规定，结合公司年度报告编制和信息披露工作的实际情况，制定 本制度。 第二条 独立董事应在公司年报编制和披露过程中切实履行职责和义务，勤 勉尽责，关注公司年度经营数据和重大事项等情况，确保公司年度报告真实、完 整、准确，不存在虚假记载、误导性陈述或重大遗漏。 第三条 独立董事在公司年报编制、审核及信息披露工作中，应会同公司审 计委员会，切实履行职责，依法做到勤勉尽责。具体包括： （一）及时听取公司管理层和财务负责人关于公司本年度生产经营、规范运 作及财务方面的情况和投、融资活动等重大事项进展情况的汇报，并尽量亲自参 与有关重大项目的实地考察； 听 ...

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

Core Viewpoint - The continuous decline in the number of shareholders in several companies indicates a trend of increasing concentration of shares, with some companies experiencing significant reductions over multiple periods [1][2]. Shareholder Trends - A total of 693 companies reported their latest shareholder numbers as of August 10, with 105 companies showing a decline for more than three consecutive periods, and some, like Kangxin New Materials, experiencing a drop for 16 consecutive periods, with a cumulative decrease of 34.63% [1]. - Other notable companies with significant declines include *ST Lanhua, which has seen a 41.59% drop over 14 periods, and companies like Ziguang Guowei and ZTE Corporation also showing a downward trend [1]. Market Performance - Among the companies with declining shareholder numbers, 70 have seen their stock prices rise, while 35 have experienced declines. Notable gainers include Jiemai Technology, which rose by 47.49%, and Hailin Pharmaceutical, which increased by 39.58% [2]. - In comparison to the Shanghai Composite Index, 46 companies (43.81%) outperformed the index, with Jiemai Technology, Hailin Pharmaceutical, and *ST Huike showing relative returns of 36.13%, 29.44%, and 29.04%, respectively [2]. Industry Distribution - The industries with the highest concentration of companies experiencing declining shareholder numbers include basic chemicals, electronics, and electrical equipment, with 13, 12, and 10 companies respectively [2]. - The distribution of these companies shows that 71 are listed on the main board, while 34 are on the ChiNext board [2]. Institutional Activity - In the past month, 8 companies with declining shareholder numbers have been investigated by institutions, with Jiemai Technology and Shuanghui Development receiving the most attention, having been surveyed 4 and 2 times respectively [2]. - The companies with the highest number of institutional participants include Dongfang Yuhong, Jiemai Technology, and Shuanghui Development, with 72, 43, and 16 institutions involved in their research [2]. Financial Performance - Among the companies that have released their semi-annual reports, Shengnong Development reported the highest year-on-year net profit growth of 791.93% [3]. - Companies like Donghua Technology and Shaanxi Guotou A also reported significant net profit increases of 14.64% and 5.74%, respectively [3]. - A total of 32 companies have issued performance forecasts, with 5 expecting profit increases and another 5 anticipating profit [3].

Group 1 - As of August 10, 273 companies listed on the ChiNext board reported their latest shareholder numbers, with 123 companies experiencing a decline in shareholder count compared to the previous period, and 7 companies seeing a decline of over 10% [1] - The company with the largest decrease in shareholder count is ST Emergency, which reported 67,076 shareholders, a decrease of 14.73% from July 31, with a cumulative drop of 29.34% in stock price since the concentration of shares began [1][3] - Other notable companies with significant declines include Yihau New Materials and Zhongyi Technology, with decreases of 14.56% and 14.16% in shareholder count, respectively [1][3] Group 2 - A total of 33 companies on the ChiNext board have shown a continuous concentration of shares, with some experiencing a decline in shareholder count for more than three consecutive periods, and one company has seen a decline for 10 consecutive periods [1] - Huaping Co. reported a continuous decrease in shareholder count for 10 periods, with a cumulative decline of 10.83%, while Zhongqi Co. and Hailin Pharmaceutical reported declines of 31.40% and 41.45%, respectively [2] - The average stock price increase for concentrated shares since August 1 is 5.03%, with Hailin Pharmaceutical, ST Huike, and Tunan Co. leading with increases of 67.27%, 50.46%, and 24.81% [2] Group 3 - Among the concentrated shares, nine companies have released their semi-annual reports, with Beiding Co. showing the highest year-on-year net profit growth of 74.92% [3] - Huizhong Co. is expected to report a median net profit of 41.01 million, reflecting a year-on-year increase of 100% [3] - The industries with the most concentrated shares include machinery, electronics, and biopharmaceuticals, with 15, 14, and 13 companies listed, respectively [2]

证券日报网讯海辰药业8月13日在互动平台回答投资者提问时表示，截至8月8日，公司股东数为22587 户。 （文章来源：证券日报） ...

证券时报·数据宝统计，截至发稿，海辰药业收盘价为49.71元，下跌3.10%，筹码持续集中以来股价累 计上涨17.60%。具体到各交易日，23次上涨，23次下跌，其中，涨停1次。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 海辰药业8月13日披露，截至8月10日公司股东户数为22587户，较上期（7月31日）减少737户，环比降 幅为3.16%。这已是该公司股东户数连续第6期下降，累计降幅达41.45%，也就是说筹码呈持续集中趋 势。 ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry, indicating that the industry index is expected to outperform the benchmark index by more than 10% [7]. Core Insights - The healthcare sector underperformed the CSI 300 index during the week of August 4 to August 8, 2025, with the Shenwan Pharmaceutical and Biological Index declining by 0.84%, lagging behind the CSI 300 by 2.07 percentage points [2][12]. - Year-to-date, the Shenwan Pharmaceutical and Biological Index has increased by 21.28%, outperforming the CSI 300 by 16.96 percentage points, ranking 5th among 31 Shenwan primary industry indices [2][14]. - As of August 8, 2025, the valuation of the pharmaceutical sector stands at 30.71 times (TTM overall method, excluding negative values), with a valuation premium of 158.50% compared to the CSI 300 [2][17]. Summary by Sections Weekly Market Review - The pharmaceutical sector's performance for the week showed a decline, with specific stocks like Nanmo Biology (+42.48%) and Haichen Pharmaceutical (+41.29%) performing well, while stocks like Nanxin Pharmaceutical (-18.50%) and Qizheng Tibetan Medicine (-16.11%) faced significant declines [3][18]. Important Events - On August 7, 2025, the Ministry of Industry and Information Technology and six other departments issued guidelines to promote the innovation and development of the brain-computer interface industry, aiming for breakthroughs in key technologies by 2027 and establishing a competitive industrial ecosystem by 2030 [4][21]. Industry Perspective - The brain-computer interface technology is highlighted as a frontier area where biological intelligence and machine intelligence can interact, with significant potential for disruptive breakthroughs. The report emphasizes the importance of this technology in the integration of life sciences and information sciences, and suggests focusing on companies like Mcland, Chengyitong, and Sanbo Neuroscience that are advancing in this field [5][22]. Investment Recommendations - The report suggests a continued focus on innovative drugs, overseas expansion, and sectors benefiting from procurement reforms. It highlights the potential for growth in the innovative drug sector, particularly in emerging markets, and recommends monitoring companies involved in insulin and orthopedic segments as well as certain generic drug firms [23].